MediniceS.A.
Other professional, scientific and technical activities, not elsewhere classified
Overview
Medinice is a company that develops advanced technologies for cardiac care, including the CoolCryo device for treating heart arrhythmias through cryoablation, which recently received FDA clearance for the U.S. market. It also offers the PacePress model, expected to be approved for the European market in 2025. Additionally, Medinice focuses on innovative solutions in cardiology and cardiac surgery.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 57.20
- High
- PLN 58.80
- Low
- PLN 56.40
- Volume
- 12.28K
- Avg. vol.
- 22.77K
- Market cap
- PLN 527.48M
- P/E ratio
- —
- EPS
- -PLN 0.86
- Shares outstanding
- 9.29M
- 52-week
- PLN 54.60 – 61.80
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLMDNCE00016
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 5.13k | USD -680.98k | USD -708.54k |
| Q1 2026 | USD 15.13k | USD -323.61k | USD -325.23k |
| Q4 2025 | USD 13.56k | USD -797.84k | USD -800.85k |
| Q3 2025 | USD 14.82k | USD -231.54k | USD -233.30k |
Results for Q3 2026:Nov 6, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2013-01-03. Active
81 1160 2202 0000 0005 4112 5292
09 1020 1068 0000 1102 0362 5431- 26 1020 1068 0000 1302 0362 5415
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 4, 2022 | Commercial Companies Code notice | |
| Nov 15, 2018 | Commercial Companies Code notice | |
| Jun 11, 2018 | Shareholders' meeting convened | |
| Feb 15, 2017 | Shareholders' meeting convened | |
| Jan 19, 2017 | Shareholders' meeting convened |
Public aid
14 public aid cases recorded, with a total value of $2,023,993.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 4, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | — | Prezydent Miasta Stołecznego Warszawy | |
| May 9, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | — | Marszałek Województwa Mazowieckiego | |
| May 9, 2025 | Aid for research and development projects: experimental development | — | Marszałek Województwa Mazowieckiego |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
If there is a one-person management board, the company is represented by 1 (one) member of the management board. If there is a multi-member management board, the company is represented by 2 (two) members of the management board acting jointly or by 1 (one) member of the management board acting jointly with a commercial proxy.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Medinice.
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Radiovetsp. z o.o. | $278,881.56 | radiovet.pl | |
| Maps Studiosp. z o.o. | $63,206.37 | mapsstudio.pl | |
| Spektrochem Coatings Laboratorysp. z o.o. | $51,290.29 | spektrochem.pl | |
| Worklife Edusp. z o.o. | $47,909.14 | worklifeedu.pl | |
| SCHE Inżynieriasp. z o.o. | $29,587.46 | sche-24.pl | |
| Skyreconsp. z o.o. | $22,541.01 | skyrecon.pl | |
| OCTO Grcsp. z o.o. | $13,058.85 | octolegal.com | |
| Warszawskie Centrum Nowych Technologiisp. z o.o. | $12,491.68 | cete.technology | |
| Hermetia Systemssp. z o.o. | $9,040.90 | hermetia.co | |
| Accountant Partnersp. z o.o. | $5,583.12 | accountantpartner.com |
Change history
| Date | Event |
|---|---|
| 2026-07-23 | Share capital change (910,999.60 PLN → 1,045,163.90 PLN) |
| 2025-12-12 | Share capital change (769,564.80 PLN → 910,999.60 PLN) |
| 2025-06-18 | Share capital change (766,229.10 PLN → 769,564.80 PLN) |
| 2024-11-21 | Share capital change (646,229.10 PLN → 766,229.10 PLN) |
| 2023-05-25 | Share capital change (627,257.50 PLN → 646,229.10 PLN) |
FAQ
Last updated: 2026-08-28